Zoetis (ZTS) Depreciation & Amortization (CF) (2012 - 2026)
Zoetis (ZTS) posted quarterly Depreciation & Amortization (CF) of $119.0 million for Q1 2026, little changed year-over-year from $119.0 million in Q1 2025, and down 1.65% quarter-over-quarter from $121.0 million in Q4 2025.
Zoetis (ZTS) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Depreciation & Amortization (CF) for 15 consecutive years, with $119.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) changed 0.0% year-over-year to $119.0 million; the TTM figure through Mar 2026 stood at $487.0 million (down 0.61% YoY), while the FY2025 annual figure was $487.0 million, down 2.01% from the prior year.
- Depreciation & Amortization (CF) fell to $119.0 million in Q1 2026 per ZTS's latest filing, from $121.0 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $127.0 million in Q2 2024 and bottomed at $114.0 million in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $121.1 million across 5 years, with a median of $121.0 million in 2023.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) advanced 7.83% — and 2025, when it dropped 5.56%.
- Zoetis' Depreciation & Amortization (CF) stood at $119.0 million in 2022, then advanced by 5.88% to $126.0 million in 2023, then declined by 2.38% to $123.0 million in 2024, then slipped by 1.63% to $121.0 million in 2025, then declined by 1.65% to $119.0 million in 2026.
- Business Quant data shows ZTS's Depreciation & Amortization (CF) at $119.0 million in Q1 2026, $121.0 million in Q4 2025, and $124.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 30.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 119.00 Mn |
| Jun 30, 2026 | 119.00 Mn |
| Mar 31, 2026 | 119.00 Mn |
| Mar 31, 2026 | 119.00 Mn |
| Dec 31, 2025 | 121.00 Mn |
| Dec 31, 2025 | 121.00 Mn |
| Sep 30, 2025 | 124.00 Mn |
| Sep 30, 2025 | 124.00 Mn |
| Jun 30, 2025 | 123.00 Mn |
| Jun 30, 2025 | 123.00 Mn |
| Mar 31, 2025 | 119.00 Mn |
| Mar 31, 2025 | 119.00 Mn |
| Dec 31, 2024 | 123.00 Mn |
| Dec 31, 2024 | 123.00 Mn |
| Sep 30, 2024 | 121.00 Mn |
| Sep 30, 2024 | 121.00 Mn |
| Jun 30, 2024 | 127.00 Mn |
| Jun 30, 2024 | 127.00 Mn |
| Mar 31, 2024 | 126.00 Mn |
| Mar 31, 2024 | 126.00 Mn |